Spots Global Cancer Trial Database for refractory cytopenia with multilineage dysplasia

Every month we try and update this database with for refractory cytopenia with multilineage dysplasia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes	NCT00398047	Leukemia Myelodysplastic...	Azacitadine and...	- 120 Years	Wake Forest University Health Sciences
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation	NCT00005641	Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic...	anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera...	15 Years - 60 Years	H. Lee Moffitt Cancer Center and Research Institute
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes	NCT00997243	Leukemia Myelodysplastic...	lintuzumab 5-azacytidine	18 Years -	Ohio State University Comprehensive Cancer Center
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT00119366	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo...	iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom...	16 Years - 50 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	NCT00002926	Leukemia Myelodysplastic...	cytarabine etoposide idarubicin allogeneic bone... peripheral bloo...	16 Years - 60 Years	National Cancer Institute (NCI)
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant	NCT00898118	Leukemia Myelodysplastic...	polymerase chai... flow cytometry laboratory biom... allogeneic hema...	- 17 Years	National Cancer Institute (NCI)
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	NCT00397813	Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra...	50 Years - 75 Years	Fred Hutchinson Cancer Center
Vorinostat in Treating Patients With Acute Myeloid Leukemia	NCT00305773	Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... Refractory Cyto... Secondary Acute... Untreated Adult...	vorinostat vorinostat	18 Years -	National Cancer Institute (NCI)
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT	NCT01012492	AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ...	Abatacept	12 Years -	Boston Children's Hospital
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT00008177	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Untreated Adult...	iodine I 131 mo... total-body irra... allogeneic hema... peripheral bloo... fludarabine pho... cyclosporine mycophenolate m... laboratory biom...	50 Years -	Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	NCT00397813	Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra...	50 Years - 75 Years	Fred Hutchinson Cancer Center
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes	NCT00104962	Childhood Myelo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Unspecified Chi...	lenalidomide	1 Year - 21 Years	National Cancer Institute (NCI)
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome	NCT00731328	Leukemia Myelodysplastic... Nonmalignant Ne... Paroxysmal Noct...	nonmyeloablativ...	- 75 Years	Asan Medical Center
Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome	NCT00513578	Myelodysplastic...	PR1 leukemia pe... incomplete Freu... sargramostim	18 Years -	National Cancer Institute (NCI)
Topotecan in Treating Patients With Myelodysplastic Syndrome	NCT00003675	Leukemia Myelodysplastic...	topotecan hydro...	15 Years - 120 Years	Alliance for Clinical Trials in Oncology
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	NCT00002926	Leukemia Myelodysplastic...	cytarabine etoposide idarubicin allogeneic bone... peripheral bloo...	16 Years - 60 Years	National Cancer Institute (NCI)
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT	NCT01012492	AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ...	Abatacept	12 Years -	Boston Children's Hospital
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes	NCT00104962	Childhood Myelo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Unspecified Chi...	lenalidomide	1 Year - 21 Years	National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Myelodysplastic Syndromes	NCT00005845	Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto...	tipifarnib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Myelodysplastic Syndrome	NCT00005853	Leukemia Myelodysplastic...	anti-thymocyte ... etanercept	-	Fred Hutchinson Cancer Center
Biological Therapy in Treating Patients With Myelodysplastic Syndrome	NCT00005853	Leukemia Myelodysplastic...	anti-thymocyte ... etanercept	-	Fred Hutchinson Cancer Center
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers	NCT00619645	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... peripheral bloo...	18 Years - 120 Years	University of California, Davis
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes	NCT00997243	Leukemia Myelodysplastic...	lintuzumab 5-azacytidine	18 Years -	Ohio State University Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: